HOME >> BIOLOGY >> NEWS
Nuclear medicine aids early diagnosis of pulmonary anthrax

Reston, VA - A nuclear medicine procedure that has the potential to safely pinpoint even the smallest amounts of infected tissue has received preliminary approval for a clinical trial in the diagnosis of inhalation anthrax before symptoms become apparent. A report on this possible breakthrough will appear in the Newsline section of the December issue of The Journal of Nuclear Medicine, available on December 19. The Newsline article can be found at: http://www.snm.org/pdf/newslinecurr.pdf

The JNM Newsline reports that the Food and Drug Administration (FDA) has approved a protocol for a clinical trial to assess the efficacy of a 99mTc-labeled monoclonal antibody in imaging early-stage inhalation anthrax infection.

According to the representatives of the company that has developed the monoclonal antibody, the technique offers the unique ability to detect the earliest stages of involvement, before any other laboratory or radiographic diagnostic tests can detect the presence of infection and well before the more serious symptoms of inhalation anthrax infection are apparent. Newsline reports that the technique promises not only to identify and begin treatment for patients in the earliest stages of infection but to provide a means by which patients can be definitively identified as disease free and taken off long-term wide-spectrum antibiotic treatment.

According to Newsline, the protocol, developed by Robert Bridwell, MD, Associate Professor of Nuclear Medicine and Radiology and the Uniformed Services University of the Health Sciences (Bethesda, MD) and staff physician at Walter Reed Army Medical Center (WRAMC; Washington, DC), is designed to identify asymptomatic patients who have experienced credible exposure to anthrax spores. Information from Bridwell obtained by SNM after the article went to press, indicated that all patients exposed will be assessed and that for ethical reasons there
'"/>

Contact: Karen Lubieniecki
karenlub@aol.com
703-683-0357
Society of Nuclear Medicine
11-Dec-2001


Page: 1 2 3

Related biology news :

1. Society of Nuclear Medicines 51st Annual Meeting June 19-23, 2004
2. Image of the Year announced by Society of Nuclear Medicine
3. Nuclear waste disposal: A safer solution?
4. Heavy Traffic At The Nuclear Pore: How Proteins And RNA Leave The Cell Nucleus
5. Nuclear Safer Than Coal?
6. Probing the surface of white blood cells to enhance immune system medicine
7. From science fiction to reality: Nanomedicine brings fresh hope to the medical world
8. Annals of internal medicine tip sheet, July 20, 2004
9. Germans must research the history of reproductive medicine during the Nazi era
10. New public policy & aging report highlights facts and fiction about anti-aging medicine
11. K-State business researchers to help with major study on food supply veterinary medicine

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Nuclear medicine aids early diagnosis pulmonary anthrax

(Date:4/1/2015)... , April 1, 2015   Medisafe ™, the ... users across iOS and Android ... integrating biofeedback into the platform to allow patients to ... For the first time, patients will be able to ... dose impacts important biometrics, such as glucose levels and ...
(Date:3/31/2015)... NEW YORK , March 31, 2015   ... announced the launch of the Post-Surgical Pain Management TRACKER, ... data products tracking usage trends in the medical device ... monthly access to data including treatment volumes, market share, ... manage the pain associated with joint surgery. ...
(Date:3/26/2015)... TORONTO , March 26, 2015 ... premier family, social, recreation and athletic club, today announced ... designed to allow freedom of movement for members and ... "Following a comprehensive process, we selected FST,s IMID ... sophistication and convenience for our members and staff, in ...
Breaking Biology News(10 mins):Medisafe Announces Launch of Biometric Integration, Enabling Patients to Stay Adherent to Their Meds and See Tangible Health Results 2Guidepoint Launches Post-Surgical Pain Management TRACKER 2Guidepoint Launches Post-Surgical Pain Management TRACKER 3Granite Club First Private Club in North America to Implement FST Biometrics Secure Access Solution, as Part of Multi-million Dollar Expansion 2
(Date:4/20/2015)... British Columbia and MENLO ... --  DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) (DelMar ... developing and commercializing proven cancer therapies in new ... at the 106th Annual Meeting of the ... Meeting on the potential for its lead product ...
(Date:4/20/2015)... , April 20, 2015  Eli Lilly and ... data from several targeted cancer therapies, reflecting Lilly,s diverse ... (AACR) Annual Meeting 2015, held April 18-22 in ... Cancer Discoveries to Patients" is the theme of this ... Lilly,s commitment to broadening its portfolio of therapies that ...
(Date:4/20/2015)... --  Meditope Biosciences, Inc ., a biotechnology company developing ... presentation of data demonstrating the use of its SnAP ... data were presented in an abstract at the AACR ... Philadelphia . "We are ... many commercial applications that may be possible for our ...
(Date:4/17/2015)... Reed Technology and Information Services Inc. ... and submission to the U.S. Food and Drug Administration ... Distribution Report (LDR) service for manufacturers of biologics, including ... FDA’s new rule on electronic submission of LDRs. ... and timing of particular biologics introduced to the marketplace, ...
Breaking Biology Technology:DelMar Pharmaceuticals Presents Promising Preclinical Data on VAL-083's Potential to Treat Temozolomide-Resistant Glioblastoma Multiforme (GBM) 2DelMar Pharmaceuticals Presents Promising Preclinical Data on VAL-083's Potential to Treat Temozolomide-Resistant Glioblastoma Multiforme (GBM) 3DelMar Pharmaceuticals Presents Promising Preclinical Data on VAL-083's Potential to Treat Temozolomide-Resistant Glioblastoma Multiforme (GBM) 4DelMar Pharmaceuticals Presents Promising Preclinical Data on VAL-083's Potential to Treat Temozolomide-Resistant Glioblastoma Multiforme (GBM) 5Lilly Releases Early-Stage Pipeline Data at AACR Annual Meeting 2015 2Lilly Releases Early-Stage Pipeline Data at AACR Annual Meeting 2015 3Lilly Releases Early-Stage Pipeline Data at AACR Annual Meeting 2015 4Lilly Releases Early-Stage Pipeline Data at AACR Annual Meeting 2015 5Lilly Releases Early-Stage Pipeline Data at AACR Annual Meeting 2015 6Meditope Biosciences Presents Data At The American Association Of Cancer Research (AACR) Annual Meeting Validating Its SnAP Technology Platform 2Reed Tech Announces FDA Lot Distribution Report (LDR) Service for Manufacturers of Biologic Products 2Reed Tech Announces FDA Lot Distribution Report (LDR) Service for Manufacturers of Biologic Products 3
Cached News: